ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Dynamics changes of spleen volume predict survival outcomes in unresectable hepatocellular carcinoma treated with tislelizumab plus lenvatinib.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling regorafenib resistance: metabolic reprogramming, tumor plasticity, and novel approaches to overcome therapy failure.Archives of pharmacal research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDynamic changes in spleen volume (SpV) may reflect immune and hemodynamic alterations in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of SpV dynamics in patients with unresectable HCC (uHCC) treated with tislelizumab plus lenvatinib.
methodsWe retrospectively analyzed 103 patients with uHCC treated with tislelizumab plus lenvatinib between June 2021 and June 2025. SpV was measured on contrast-enhanced CT at baseline and approximately 3 months post-treatment using AI-assisted segmentation with manual correction. The absolute SpV change (ΔSpV) and monthly SpV change rate were calculated. The optimal cut-off values were identified via maximally selected rank statistics. Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression models.
resultsPost-treatment SpV increase was observed in 65% of patients and was associated with shorter progression-free survival (PFS). Both ΔSpV and SpV change rate were independent predictors of PFS (HR for ΔSpV: 1.005, P = 0.01; HR for change rate: 1.02, P < 0.00). Cut-off values of 23.81 cm
conclusionSpV dynamics provide a noninvasive imaging biomarker for identifying uHCC patients at elevated risk of progression during tislelizumab plus lenvatinib therapy. Incorporating these volumetric metrics into routine imaging may enhance prognostic assessment and guide risk-adapted patient management.
Indexed as
Identifiers
41801594What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.